Cancers, Vol. 11, Pages 1185: Targeted Treatment Options of Recurrent Radioactive Iodine Refractory H ürthle Cell Cancer

Conclusions: In progressive HCC, several treatment options outside or inside clinical trials are available. WGS of metastatic tumors might direct the timing of therapy. Unlike other cancers, the absence of RAS variants seems to provide insufficient justification of single-agent panitumumab administration in HCC cases harboring a near-homozygous genome.

Source: Cancers - August 14, 2019 Category: Cancer & Oncology Authors: Mehtap Derya Aydemirli Willem Corver Ruben Beuk Paul Roepman Nienke Solleveld-Westerink Tom van Wezel Ellen Kapiteijn Hans Morreau Tags: Article Source Type: research